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Abstract 
Background: Allergic asthma and rhinitis are common in pregnancy. The immune mechanisms 
underlying the effects of pregnancy in asthma and vice-versa are not completely understood.  
Objectives: This work aimed to study the evolution of regulatory T and B cells in asthmatic pregnant 
women, from late pregnancy till postpartum.  
Methods: Four groups of women were enrolled for this study: third trimester pregnant women, 
asthmatic (n=24) and healthy (n=43), and non-pregnant women, asthmatic (n=33) and healthy (n=35). 
Pregnant women were also evaluated postpartum (>6 weeks after delivery). Blood samples were taken 
from each woman and flow cytometry was used to characterize circulating regulatory T and B cells. 
Foxp3 expression was assessed within CD4DimCD25Hi regulatory T cells. 
Results: In asthmatic and healthy pregnant women, regulatory T cells did not oscillate significantly from 
pregnancy to postpartum, but CD24HiCD38Hi regulatory B cells, decreased in pregnancy, rose significantly 
postpartum. Foxp3 expression in regulatory T cells was also impaired during pregnancy in asthmatic and 
healthy pregnant women, recovering postpartum. Nevertheless, asthmatic pregnant women presented 
higher Foxp3 expression than healthy pregnant women (p=0.007), probably due to the use of control 
medication. 
Conclusions: Women with controlled asthma present variations in regulatory cell subsets during 
pregnancy and postpartum. The similar pattern observed for Foxp3 expression and CD24HiCD38Hi 
regulatory B cells during this period corroborates the interaction established between regulatory T and 
B cells in immune responses. Considering the immunomodulatory potential of these immune mediators, 
more studies are needed to evaluate their relation with asthma and rhinitis complications in pregnancy. 
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Resumen 
 
Antecedentes: El asma y la rinitis alérgica son enfermedades comunes durante el 
embarazo. A pesar de ello, no están completamente esclarecidos los mecanismos 
inmunológicos del embarazo implicados en el asma y viceversa. 
Objetivos: Este trabajo tuvo como objetivo el estudiar la evolución de los linfocitos T y 
B reguladores en mujeres asmáticas embarazadas, desde fases tardías del embarazo 
hasta después del parto. 
Métodos: Se incluyeron cuatro grupos de mujeres para este estudio: mujeres 
embarazadas en su tercer trimestre, asmáticas (n = 24) y sanas (n = 43), y mujeres no 
embarazadas, asmáticas (n = 33) y sanas (n = 35). Las mujeres embarazadas también 
fueron evaluadas después del parto (> 6 semanas después del parto). Se tomaron 
muestras de sangre de cada mujer y se realizó citometría de flujo para caracterizar los 
linfocitos T y B reguladores circulantes. La expresión de Foxp3 se evaluó en los 
linfocitos T reguladores CD4DimCD25Hi. 
Resultados: En las mujeres embarazadas, tanto sanas como asmáticas, los linfocitos T 
reguladores no oscilaron de manera significativa desde el embarazo hasta después del 
parto. Sin embargo, en los linfocitos B reguladores CD24HiCD38Hi, se observó una 
disminución durante el embarazo que aumentó significativamente después del parto. 
La expresión de Foxp3 en los linfocitos T reguladores también se vio alterada durante 
el embarazo tanto en las mujeres embarazadas asmáticas como en las sanas, 
normalizándose en el posparto. No obstante, las mujeres asmáticas embarazadas 
presentaron niveles de expresión de Foxp3 superiores a los de las mujeres 
embarazadas sanas (p = 0,007), probablemente debido a la utilización de medicación 
de control. 
Conclusiones: Las mujeres con asma controlada, durante el embarazo y después del 
parto, presentan variaciones en los diferentes subtipos linfocitos reguladores. El similar 
comportamiento que se observa para la expresión de Foxp3 y los linfocitos B 
reguladores CD24HiCD38Hi apoya la interacción que se establece en la respuesta 
inmunitaria, entre los linfocitos T y B reguladores, durante este período. Teniendo en 
cuenta el potencial inmunomodulador de estos mecanismos, se necesitan más 
estudios para evaluar su relación con las complicaciones del asma y la rinitis durante 
el embarazo. 
 
Palabras clave: Atopia, embarazo, postparto, linfocitos humanos T reguladores, 
linfocitos humanos B reguladores, citometría de flujo 
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Introduction 
For women in fertile age, allergic asthma and rhinitis can present risks for pregnancy [1]. Disease course 
may improve, remain unchanged, or worsen during pregnancy, and asthma exacerbations may have a 
significant impact in fetal development and birth weight, besides being related with preterm delivery 
[1]. Also, maternal asthma is a risk factor for the development of asthma in asthmatic women´s progeny 
[2].  
Pregnancy challenges the immune system, as it must assume tolerance towards the semi-allogenic 
fetus, without compromising mother defenses. Th2 cells, hallmark of atopic diseases, are typically 
associated to gestation and appear to contribute to the maintenance of pregnancy [3]. Nonetheless, 
more than biased Th2 immune response, pregnancy presents rather strict regulatory mechanisms that 
balance cytokine production [4].  
Regulatory T cells (Tregs) are known to be expanded during early pregnancy [5], and seem to be 
decreased and/or functionally impaired in asthmatics [6, 7]. Yet, Tregs and IL10, an anti-inflammatory 
cytokine secreted by these cells, have been implicated in asthma´s amelioration [8]. Recently, B cells 
have been considered to have an important role in Th2 responses and airway inflammation [9]. As for 
regulatory B cells (Bregs), its impaired regulatory activity was also reported in allergic asthma [10], and 
Bregs have a close relation to Tregs [11].  
Modifications in T and B cell subsets in healthy [12-14] and asthmatic [15, 16] pregnant women have 
been reported. However, not much is known about B cells neither about the immune profile in 
postpartum, when an immune reactivation is believed to happen [17].  
Our aim was to monitor pregnant women with asthma, from late pregnancy till postpartum in order to 
characterize Tregs, Bregs and IL10 expression, and the impact of pregnancy on these immune 
parameters.  
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Methods 
Study Subjects 
Sequential pregnant women with atopic asthma (AP), healthy pregnant women (HP), as well as non-
pregnant women with atopic asthma (ANP) and healthy non-pregnant women (HNP) of reproductive 
age followed at CUF Descobertas Hospital were enrolled for this study. All women were informed about 
the nature of the study and provided written informed consent at recruitment. Blood samples were 
collected once for non-pregnant women and twice for pregnant: the pregnancy time point occurred in 
the third trimester of gestation ( between weeks 31 and 36 of gestation) and the postpartum time point 
at least 6 weeks after delivery. All women completed questionnaires for demographic and clinical data 
in each time point. Diabetes; hypertension; autoimmune diseases; any active infectious disease 
including hepatitis and HIV; any other allergic (except for atopic dermatitis and allergic rhinitis) or 
respiratory disease; and smoking for the last 6 months before sample collection, represented exclusion 
criteria for all groups. Multiple gestation, pregnancy complications and prenatal use of any medication 
(other than vitamins, folic acid, and iron supplements) were exclusion criteria for HP. The same criteria 
were applied to AP, except for therapeutics. 
 AP and ANP groups included women with both atopic asthma and rhinitis, physician diagnosed 
according to current international guidelines [18-20], with documented sensitization to aeroallergens 
(by skin prick tests and/or specific IgE quantification). Immunotherapy, performed in the past or 
present, was considered an exclusion criteria for AP and ANP. Asthma and rhinitis were treated 
according to the current guidelines [19, 20]. All AP and ANP were under inhaled corticosteroid (ICS) 
therapy (low-median dose, 200-400 ug beclomethasone /daily), and/or long-acting Beta-agonists (LABA) 
and antileukotrienes. At recruitment, AP and ANP presented no asthma exacerbation for at least 6 
weeks before sample collection. Asthma symptoms were evaluated according to GINA guidelines [19, 
20], using daytime symptoms, night waking due to asthma, reliever needed for symptoms and activity 
limitation due to asthma in the assessment of disease control. Table 1 resumes demographic and 
anthropometric data. 
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The study was approved by CUF Descobertas Hospital and NOVA Medical School Ethics Committees. All 
investigations were conducted according to the Declaration of Helsinki. 
 
Regulatory T and B cells 
Peripheral blood samples were collected into EDTA-containing tubes using standard aseptic 
venipuncture techniques. Cells were processed less than 24 hours after collection.  
For Tregs phenotyping, the Human FoxP3 Buffer Set (BD Pharmingen, San Jose, CA) was used, according 
to the manufacturer’s instructions. First, cells were lysed with BD FACS Lysing (BD Biosciences), and 
incubated with anti-CD25 PE (clone BC96, Biolegend, San Diego, CA) and anti-CD4 PerCP Cy5.5 (clone 
SK3, Biolegend). After being fixed and permeabilized with the reagents supplied in the kit set, cells were 
stained with Anti-Foxp3 Alexa Fluor 488 (clone 259D/C7, BD Pharmingen). At least 10,000 CD4+T cells 
were acquired. 
For the evaluation of Bregs, the panel of mAbs included anti-CD19 PerCP Cy5.5 (clone HIB19, Biolegend), 
anti-CD24 PE (clone ML5, Biolegend), anti-CD27 FITC (clone O323, Biolegend) and anti-CD38 APC (clone 
HIT2, Biolegend). A lyse-wash protocol was used. Briefly, cells were incubated for 15 minutes with 
monoclonal antibodies (mAbs), and then lysed with BD FACS Lysing (BD Biosciences). Acquisition was 
performed after a wash step with PBS. At least 2,000 CD19+ B cells were acquired. 
 
Cell culture for intracellular cytokine stimulation  
Heparin whole blood was used to evaluate IL10 expression in T and B cells. Cells were stimulated with 
PMA (50ng/mL; Sigma Aldrich, St. Louis, MO), calcium ionophore (1µg/mL, Sigma Aldrich) and LPS 
(10µg/mL, Sigma Aldrich) [21], and incubated for 5h, at 37ºC in a 5% CO2 atmosphere, in the presence of 
Brefeldin A (1.0μg/ml, BD Pharmingen). For each sample, unstimulated tubes were incubated in parallel, 
and were further used as stimulation and staining controls. The protocol was performed according to 
the instructions of Cytofix-Cytoperm kit (BD Pharmingen). Briefly, the initial surface staining step 
included an incubation with anti-CD3-FITC (clone SK7, BDBiosciences), anti-CD8 APC (clone SK1, 
Biolegend) and anti-CD19 PerCP Cy5.5 (clone HIB19, Biolegend). After fixing and permeabilizing, cells 
were marked with anti-IL10 PE (clone JES3-19F1, Biolegend). A minimum of 2,000 B cells (CD19+) or 
10,000 T cells (CD3+) were acquired. 
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Multicolor Flow Cytometry and Data Analysis 
Flow cytometry was performed in a 4-color BD FACSCalibur (BD Biosciences, San Jose, CA), equipped 
with a 488nm blue laser and a 647nm red laser. Equipment setup, calibration and quality control 
protocols were performed to assure trough time stability in measurements. Figure 1 presents the gating 
strategy for Treg assessment and Foxp3 expression (assessed in geometric mean values of Mean 
Fluorescence Intensity (MFI) units). To reduce the impact of day-to-day variation on this evaluation, a 
ratio between the MFI of Foxp3 in CD4DimCD25Hi Tregs and the MFI of Foxp3 in CD4- Lymphocytes was 
performed. The gating strategy for Bregs subsets and IL10 secretion are presented in Figures 2 and 3.   
All evaluations were performed directly in whole blood. 
Statistical Analysis 
Absolute frequencies were used in categorical variables, expressed also as percentages, and analyzed by 
Fisher’s exact test or Chi-square. D'Agostino & Pearson test was carried out to assess normality of 
distributions. Data normally distributed were presented as mean±standard deviation, otherwise as 
median and interquartile range. Multiple group evaluation was performed with One-way ANOVA 
(ANOVA I) or Kruskal-Wallis test, followed by Tukey’s or Dunn’s multiple comparison tests, respectively. 
Regarding paired groups, data were analyzed with paired Student’s t-test or Wilcoxon test. Unpaired 
Student’s t-test or Mann–Whitney test were used to compare each 2 independent groups. 
Statistical significance was defined by a p-value <0.05. All data were analyzed using GraphPad Prism 
software, version 6.01 for Windows (GraphPad Software, La Jolla, California, USA, 
http://www.graphpad.com). Tukey box-and-whiskers graphs, also obtained with GraphPad Prism, were 
used to present results. 
 
Results 
Demographic and anthropometric data 
Demographic and anthropometric evaluations are summarized in Table 1. Analyzing all groups of 
women (AP, n=24; ANP, n=32; HP, n=43; HNP, n=35) for demographic data, statistical significance was 
observed in the comparison of Body Mass Index (BMI). As for BMI, Kruskal-Wallis test presented a 
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significant p-value, with the subsequent Dunn's multiple comparisons reporting significantly higher BMI 
values in pregnant women (p<0.001 for HP vs HNP and p=0.001 for AP vs ANP). Regarding parity, AP and 
HP groups were comparable.  
Asthma and/or rhinitis complications were reported as illustrated in Table 1: 4 (16.7%) AP presented 
asthma exacerbations and 2 (8.3%) presented rhinitis (nasal symptoms) in the 3rd trimester of 
pregnancy. Postpartum, 1 AP (4.2%) reported asthma exacerbation and 2 AP (8.3%) reported rhinitis 
(nasal symptoms). None of these complications required hospitalization or treatment at emergency 
department. Though medicated during pregnancy, postpartum only 13 AP (54.2%) remained under 
therapeutics (ICS therapy and/or LABA and antileukotrienes).  
Final postpartum measurements were carried out on median 44 (8) days after delivery. 
Increase of CD4+CD25HiFoxp3+ Tregs in ANP and in AP postpartum  
In the comparison of non-pregnant asthmatic and non-asthmatic patients, significant differences were 
observed in CD4+CD25HiFoxp3+ Tregs (p=0.002), increased in ANP (Figure 4.a). 
Following the evolution of pregnant women from 3rd trimester of pregnancy to postpartum, no 
differences were reported either within AP or HP in the paired evaluation of time points.. Comparing 
Tregs of 3rd trimester pregnant women vs non-pregnant women, no significant differences were  found 
for the comparisons of AP vs ANPand HP vs HNP. Nevertheless, in postpartum, Tregs were increased in 
both AP and HP compared to HNP (AP vs HNP, p=0.041; HP vs HNP, p=0.005), which seems to point 
towards an increase of Tregs after pregnancy. 
Foxp3 expression is increased in asthmatic women, but oscillates from pregnancy to postpartum  
We also studied the levels of Foxp3 expression in CD4DimCD25Hi Tregs (Figure 4.a). In ANP, Foxp3 
expression was augmented (p<0.001) compared to HNP.  
During pregnancy, and at least until delivery (data not shown), decreased Foxp3 expression within 
CD4DimCD25Hi Tregs was observed in both AP and HP. This decrease was more pronounced in HP, with 
poorer expression levels then the ones observed in AP (p=0.007). Both groups of women significantly 
down regulated Foxp3 expression in the third trimester of pregnancy, compared to non-pregnant 
women (vs ANP and vs HNP; p<0.001). Postpartum,Foxp3 expression levels increased significantly in AP 
and HP, compared to the values observed in the 3rd trimester of pregnancy (p<0.001). AP reached 
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expression levels similar to the ones observed in ANP; HP recovered their Foxp3 expression levels as 
well, reaching values similar to HNP.   
CD24HiCD38Hi regulatory B cells are augmented postpartum in AP and HP 
As displayed in table 2, CD24HiCD27+ Bregs showed similar levels in all groups of women studied, and in 
all time points. Thus, no differences were observed either in their monitoring from pregnancy to 
postpartum in AP and HP (Figure 4.b).  CD24HiCD38Hi Bregs, a transitional subset of B cells, displayed 
mostly pregnancy-associated changes.  First, considering ANP vs HNP, comparable values were 
obtained. No differences were reported regarding comparisons of AP vs HP, in the time points analyzed. 
Along pregnancy, CD24HiCD38Hi Bregs fluctuate with the same pattern observed for Foxp3 expression: 
reduced proportions of circulating CD24HiCD38Hi Bregs during pregnancy in AP and HP (compared to 
non-pregnant controls; p≤0.004).  Postpartum, both AP and HP raised significantly the proportions of 
CD24HiCD38Hi Bregs, compared to the levels observed in the 3rd trimester of pregnancy (p<0.001), but 
also compared to ANP and HNP (p≤0.003).  
In 3rd trimester, a positive correlation was found between CD24HiCD38Hi Bregs and the levels of Foxp3 
expression in HP (p=0.002, r=0.457; Spearman correlation test), but significance is lost postpartum. 
In ANP, the percentages of IL10-secreting T cells (CD3, CD4 and CD8) were increased compared to HNP 
(p=0.024 for CD3; p=0.034 for CD4; p=0.009 for CD8). However, 3rd trimester AP presented only 
significantly increased percentages of IL10-secreting B cells, but not T cells, compared to both HP 
(p=0.022) and HNP (p=0.008). Postpartum, IL10-secreting T cells (CD3 and CD8) were again augmented 
in AP compared to HNP (p=0.046 for CD3; p=0.016 for CD8), but also IL10-secreting B cells (p=0.031). 
Curiously, in postpartum, HP presented higher percentages of IL10-secreting B cells compared to HNP 
(p=0.019), possibly sustaining an impaired IL10 production by B cells in healthy pregnancy. Within the 
pregnant women groups (AP and HP), paired analyses revealed no significant changes from pregnancy 
to postpartum in AP, but a significant increase of IL10-secreting B cells in HP in the later evaluation 
(p=0.037), as displayed in figure 4.c. 
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Discussion 
Regulatory cells have an important role in immune tolerance and inflammation. To our knowledge this is 
the first study to report variations of regulatory T and B cell subsets in women with asthma, from the 
third trimester of pregnancy till postpartum, addressing also IL10 secretion profiles. It seems that 
though Tregs do not oscillate expressively along this period, CD24HiCD38Hi Bregs decrease in the third 
trimester of pregnancy, and present an important increase postpartum, in both asthmatic and healthy 
women. Moreover, the reduction of Foxp3 expression in Tregs in late pregnancy (and at least until 
delivery), was also overcome 6 weeks after delivery. Considering IL10 production, women with asthma 
presented distinguishing features from healthy, with more IL10 producing T cells than HNP. In the 3rd 
trimester of pregnancy, IL10-secreting B cells were augmented in AP, compared to HP, but no 
differences were reported in postpartum.  
Tregs have been involved in several human pathologies . Their number increases during early pregnancy 
and declines from mid-gestation onwards [5]. As observed in our study, other authors reported similar 
Tregs percentages in third trimester pregnant women and non-pregnant controls [5, 22]. Wegienka et 
al. [23], reported a progressive augment of Tregs percentages from the prenatal period until the first 12 
months postpartum, in both atopic and non-atopic patients, similarly to our findings. Despite our 
monitoring timings are not the same, we also found that at 6 weeks after delivery, both AP and HP 
presented higher percentages of Tregs compared to healthy non-pregnant controls. Different strategies 
for cell identification, distinct gestational periods or confrontation with animal models are also possible 
additional biases. 
Our results shown that pregnant and non-pregnant women, with controlled asthma, present higher 
percentages of Tregs than HNP, which are maintained in postpartum. Some studies have already 
reported an increased Tregs population in children with asthma under ICS treatment, compared to non-
asthmatic age-matched controls [24]. Nevertheless, Bohacs et al. [15] reported comparable Tregs in 
healthy non-pregnant and asthmatic (pregnant and non-pregnant) women, although asthmatics 
presented higher values. Similar values for Tregs were reported in asthmatic patients taking ICS, 
independently of the regularity on its intake. We also observed comparable values in treated and 
untreated AP in postpartum (data not shown). Taking into consideration that all AP had been under ICS 
during pregnancy, the similarity in postpartum values in both groups of patients (treated and untreated) 
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may suggest that the impact of ICS in circulating Tregs frequency may be sustained even after the 
treatment is stopped. Another effect of ICS is the upregulation of Foxp3 expression. Karagiannidis et al. 
[25] reported that ICS-treated asthmatic patients presented significantly higher values of Foxp3 
expression than healthy controls. By contrast, Provoost et al. [26] only reported augmented expression 
in ICS treated asthmatics compared to untreated patients, but not compared to healthy controls. 
Methodological differences can justify these opposite results; nevertheless, our data seem to be in 
accordance with Karagianiddis [25]. Not only ANP presented higher Foxp3 expression than HNP, but 
also, during pregnancy, AP showed  higher levels compared to HP. Yet, an important decrease in Foxp3 
expression in pregnancy was observed in both AP and HP. Recently, progesterone receptors have been 
identified in Tregs [27], supporting the immunomodulatory potential of pregnancy hormones. Without 
compromising the regulatory potential of Tregs during pregnancy, and even promoting their 
proliferation [28] and proportions [29], progesterone and 17β-estradiol are thought to reduce Foxp3 
expression on Tregs in second trimester pregnant women [30]. Our data support these findings, 
extending this decrease to the third trimester of gestation. Furthermore, we have shown that ICS-
treated AP also have this pregnancy-derived decrease of Foxp3 expression, though maintaining higher 
values than HP. Recognizing that Foxp3 expression can be induced in activated T cells, and that our 
study did not assess the functional status of Tregs, we can only speculate a functional normality for 
these cells in AP. Considering the protective role of Tregs towards asthma manifestations [31], AP 
presenting controlled asthma at recruitment is in favor of a normal function of regulatory cells in these 
patients. Nevertheless, further studies are needed to complete and confirm our observations. 
In postpartum, Foxp3 expression levels normalized in AP and HP, reaching non-pregnant controls, 
reinforcing that pregnancy induces modulation of Foxp3 expression.  
Bregs evaluation in asthmatic pregnant women constitutes the innovation of our study. The regulatory 
capacities of B cells have been recently reported [32], though there´s a lack of consensus on their 
phenotype [33]. Both CD24HiCD27+ and CD24HiCD38Hi B cell subsets have been considered to have 
regulatory functions, namely by the secretion of IL10 [10, 34]. Patients with asthma and/or AR have 
shown decreased frequencies of CD24HiCD27+ Bregs [10, 35], but increased CD24HiCD38Hi Bregs has also 
been spotted in asthmatic patients without medication [10]. In our study, Bregs subsets presented no 
differences comparing asthmatic to non-asthmatic patients, but unlike the previous study, our patients 
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were under medication. As defended for Tregs [24], our data suggest that the beneficial effects of 
therapeutics (such as ICS) in the course of atopic diseases can also be related to the normalization of 
Bregs frequencies in treated patients.  
Interestingly, CD24HiCD38Hi Bregs are modulated by pregnancy. Pregnancy is associated with B cell 
lymphopenia and B cell lymphopoiesis arrestment [13], which probably decreases circulating transitional 
B cell subsets such as CD24HiCD38Hi Bregs. These modifications were importantly overcome in 
postpartum, with CD24HiCD38Hi Bregs reaching levels significantly higher than those observed in non-
pregnant controls, traducing maternal immune system’s recovery after gestation. Interestingly, in mice, 
transitional B cells express high levels of prolactin receptors and hyperprolactinemia has been shown to 
increase transitional but not mature B cells [36]. A prolactin-mediated response can thus explain the 
accumulation of transitional B cells postpartum, when the hormone levels raise up to 30 times, 
compared to pre-pregnancy levels [37].   
It is believed that the promotion of Tregs differentiation is one of the mechanisms by which 
CD24HiCD38Hi Bregs operate in healthy individuals [34]. Thus, the elevation of CD4+CD25HiFoxp3+ Tregs 
postpartum in HP and AP, also reported by other authors [23], may be mediated by CD24HiCD38Hi Bregs. 
Recent experimental data also concluded that CD24HiCD38Hi Bregs promote Foxp3 expression in co-
cultured CD4 T cells [34]. In our study, Foxp3 expression and CD24HiCD38Hi Bregs evolved similarly from 
pregnancy to postpartum, and there was a positive correlation between these parameters in HP, 
reinforcing the idea of Bregs modulating Tregs.  
The profile of CD24HiCD38Hi Bregs and Foxp3 expression is comparable in asthmatic and non-asthmatic 
women, sustaining a pregnancy-derived pattern, independently of either therapeutics or asthma and 
rhinitis.  
Studies approaching IL10 production by PBMCs during pregnancy described similar levels before 
pregnancy and in late pregnancy [38]. In line with these reports, our data showed that IL10-secreting  T 
and B cells were similar in 3rd trimester HP women, compared to HNP. However, in postpartum, HP 
presented increased frequencies of IL10+ B cells after LPS stimulation. The increase of circulating 
CD24HiCD38Hi Bregs in postpartum (the subset in which IL10 secretion is mainly described in B cells) [32, 
34], could be a possible explanation. Other studies addressed the production of IL10 in asthmatic and 
allergic women, usually analyzing total PBMC secretion and serum levels [39, 40]. Although no 
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differences in PBMC production were identified comparing asthmatic and non-asthmatic women [39], 
IL10 serum levels were increased in allergic mothers (at delivery) and their children [40]. As far as we 
know, we report for the first time the distinct profiles of IL10-secreting T and B cells in asthmatic 
pregnant and non-pregnant women. We stress out that ANP presented increased IL10-secreting T cells, 
but during pregnancy IL10-secreting B cells were increased in asthmatic women, compared to healthy 
ones. Nonetheless, Tregs can secrete IL10, as well as other subsets of T cells, such as Th2 cells [4]. Th2 
cells, associated to both pregnancy and allergic diseases, may support the similar levels observed 
amongst AP, ANP and HP. However, during pregnancy, AP have a distinct capacity of B cells to secrete 
IL10, compared to HP and HNP, presenting similar (vs HP) or even lower (vs HNP) frequencies of 
CD24HiCD38Hi Bregs. Corroborating what was observed in ANP, in postpartum, AP also presented 
increased IL10-secreting B and T cells, compared to HNP. 
At follow-up, we realized that several AP women stopped therapeutics during postpartum. Considering 
the distinguishing features of immune profiles in postpartum, we compared AP with and without 
therapeutics, and concluded that studied parameters were similar in both subgroups, being 
independent from therapeutics.  
Monitoring AP pre-pregnancy and throughout more pregnancy time points would have been ideal, 
thought difficult to accomplish from a financial and practical point of view. Nevertheless, important 
immune events are known to occur during the 3rd trimester of pregnancy, recovering in the postpartum, 
as we were also able to identify in our study. 
Overall, we conclude that pregnant women with controlled asthma present a similar profile towards 
healthy pregnant women, though with few distinctive features regarding mostly Foxp3 expression.  The 
changes observed in postpartum reinforce the idea of being pregnancy-dependent, probably hormone 
driven. More studies will clarify if these parameters can be used to assess complications during 
pregnancy in women with asthma and eventually influence the immune profile of the asthmatic 
women’s offspring. 
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Figure 1. Gating strategies for the identification of distinct regulatory T cells subsets.  
A-B. The first step of the analysis of Tregs was the identification of CD4+ T cells, recognized as 
the CD4+ cells within the lymphocyte gate. C-D. Identification of CD4+CD25HiFoxp3+ regulatory T 
cells with dot plots of FMO (C) and Foxp3 (D) tubes. E. CD4 vs CD25 dot plot, showing the 
identification of CD4DimCD25Hi regulatory T cells. F. Histogram with Foxp3 expression within 
CD4DimCD25Hi regulatory T cells (grey line), overlaid on Foxp3 expression within CD4- 
Lymphocytes (black line). Geo MFI means were further in the ratio MFI of Foxp3 in 
CD4DimCD25Hi/MFI of Foxp3 in CD4- Lymphocytes.  
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Figure 2. Gating strategies for the identification of distinct regulatory B cells subsets.  
B cells were identified as the CD19+ population within the lymphocyte gate, as displayed in dot 
plots A and B. C and D dotplots present the identification of regulatory B cells subsets 
according to their expression of CD24, CD27 and CD38 (CD24HiCD27+ Bregs and CD24HiCD38Hi 
Bregs).  
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Figure 3. Gating strategies for the identification IL10 secretion in T and B cells.  
A-B. T cells were identified according the their positive expression of CD3 as shown in the 
CD3/SSC (Side Scatter) dot plot, and were further gated in CD8 negative T cells (CD4) and CD8 
positive T cells (CD8), according to their expression of CD8. C-D. CD19+ B cells (gated as shown 
in Figure 2)  and CD4+ and CD8+ T cells (gated as shown in Figure 3 – A and B) were analyzed for 
the expression of IL10, after stimulation with PMA+Ionomycin and LPS. Unstimulated samples 
(C) were used to assess the cutoff for the expression of IL10 after stimulation in B cells, CD3, 
CD4 and CD8 T cells (D).  
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Figure 4. Immune parameters in HNP, HP, ANP and AP 
a) Representative Tukey box-and-whiskers of CD4+CD25HiFoxp3+ Regulatory T cells subsets 
frequencies and Foxp3 expression within CD4DimCD25Hi Tregs in HNP, HP, ANP and AP, 
including the postpartum evaluation of pregnant women.  
b) Representative Tukey box-and-whiskers of circulating Regulatory B cells subsets frequencies 
in HNP, HP, ANP and AP, including the postpartum evaluation of pregnant women. 
c) Representative Tukey box-and-whiskers of IL-10 secreting T and B cells in HNP, HP, ANP and 
AP, including the postpartum evaluation of pregnant women.  
All comparisons performed with Mann-Whitney U, except paired groups comparisons (AP vs 
AP PP; and HP vs HP PP), which were performed with Wilcoxon test. 
Central line: median; box: interquartile range; whiskers: range; dots: outliers.  
* p<0.05; ** p<0.001. AP – Asthmatic pregnant women; ANP – Asthmatic non-pregnant 
women; HP – Healthy pregnant women; HNP – Healthy non-pregnant women; PP – 
postpartum. 
 
4 .a
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Table 1. Demographic and anthropometric comparisons between the groups of women 
recruited. 
 
a Kruskal-Wallis Test, b Chi-square test, c Unpaired Student’s t test, d Fisher exact test, e 
Mann-Whitney U. 
AP – asthmatic pregnant women, ANP – asthmatic non-pregnant women, HP – healthy 
pregnant women, HNP – healthy non-pregnant, IQR – interquartile range, sd – standard 
deviation. 
 
 
AP 
n=24 
ANP 
n=32 
HP 
n=43 
HNP 
n=35 
p-value 
Maternal age in years, median (IQR)  
 34 (4) 36 (6) 32 (5) 35 (4) 0.063a 
Ethnicity, n (%)   
Caucasian 24 (100.0) 32 (100.0) 42 (97.7) 35 (100.0) 
0.545b 
 Black 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0) 
BMI in kg/m2, median (IQR) 
 26.2 (4.5) 21.9 (5.0) 25.6 (4.1) 21.1 (2.4) <0,001a 
Education, n (%) 
Basic / High school   2 (8.3) 5 (16.1) 4 (9.3) 7 (2.3) 
0,296b Higher education 22 (91.7) 26 (83.9) 39 (90.7) 23 (76.7) 
Parity, n (%) 
Nuliparous 12 (50.0) - 24 (55.8) - 
0.799d Multiparous 12 (50.0) - 19 (44.2) - 
Smoke exposure during pregnancy, n (%) 
Yes 3 (12.5) - 7 (16.3)  - 1.000d 
No 22 (91.7)  36 (83.7)   
Gestational age (complete weeks) at evaluation, mean (sd) 
 33 (0.9) - 33 (1.1) - 0.265c 
Gestational age (complete weeks) at parturition, mean (sd) 
  39 (1.1) - 39 (1.1)  -  0,296c 
Weight at birth in grams, mean (sd) 
 3262 (329) - 3199 (402) - 0.493c 
Baby Gender, n (%) 
Male 12 (50.0) - 21 (48.8) - 
1.000d Female 12 (50.0) - 22 (51.2) - 
Days after labour in postpartum, median (IQR) 
 44 (8) - 44 (5) - 0.589b 
Breast feeding, n (%) 
Yes   23 (95.8) - 33 (76.7) - 
0.082d No 1 (4.2) - 10 (23.3) - 
Sensibilization to aeroallergens, n (%) 
D. pteronyssinus 15 (62.5) 21 (65.6) - - 1.000d 
D. farinae  12 (50.0) 18 (56.3) - - 0.788d 
Lepidoglyphus destructor 2 (8.3) 9 (28.1) - - 0.093d 
Grass polens 25 (20.8) 14 (43.8) - - 0.092d 
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Table 2. Percentages and absolute counts of T and B cell subsets analyzed in AP, ANP, HP and HNP women. 
Celular Subset AP 
(n=24) 
AP PP 
(n=24) 
ANP 
(n=32) 
HP  
(n=43) 
HP PP 
(n=43) 
HNP 
(n=35) 
Regulatory T cells       
CD4+ CD25Hi Fox p3+ (%) 6.14 (1.54) 5.90 (2.43) 6.88 (2.17) 6.07 (3.44) 6.63 (2.85) 5.48 (1.69) 
CD4+ CD25Hi Fox p3+ (Cells/µL) 52 (22) 65 (29) 83 (33) 50 (25) 71 (39) 56 (31) 
Foxp3 expression in CD4DimCD25Hi    1.64 (1.26) 1.94 (0.46) 2.09 (0.43) 1.49 (0.19) 1.93 (0,30) 1.80 (0.25) 
Regulatory B cells       
CD24HiCD27+ (%) 25.47 (16.75) 27.26 (20.46) 31.77 (13.37) 26.92 (15.02) 25.76 (14.30) 27.46 (49.80) 
CD24HiCD27+ (Cells/µL) 45 (47) 59 (45) 102 (97) 44 (41) 57 (47) 54 (40) 
CD24HiCD38H (%) 1.87 (2.97) 7.13 (8.84) 3.84 (2.74) 1.42 (1.38) 5.62 (5.58) 3.63 (2.48) 
CD24HiCD38Hi (Cells/µL) 3 (4) 14 (25) 12 (7) 2 (2) 11 (14) 8 (8) 
IL-10 secreting cells       
IL10+ CD3+ T cells (%) 0.83 (0.69) 0.91 (0.70) 0.94 (0.46) 0.77 (0.47) 0.83 (0.50) 0.72 (0.57) 
IL10+ CD3+ CD4+ (CD8-) T cells (%) 1.00 (0.76) 1.03 (0.78) 1.04 (0.71) 0.92 (0.54) 0.95 (0.53) 0.84 (0.54) 
IL10+ CD3+ CD8+ T cells (%) 0.66 (0.69) 0.65 (0.86) 0.73 (0.51) 0.49 (0.55) 0.59 (0.47) 0.40 (0.59) 
IL10+ CD19+ B cells (%) 1.26 (0.67) 1.24 (0.83) 1.04 (0.73) 1.00 (0.90) 1.17 (0.91) 0.92 (0.70) 
 
 
All results are presented as median (IQR). 
AP – asthmatic pregnant women, ANP – asthmatic non-pregnant women, HP – healthy pregnant women, HNP – healthy non-pregnant, IQR – interquartile range, 
PP - postpartum. 
 
 
 
